Objective To investigate the expression of tyrosine protein kinase CD117 in non-M3 acute myeloid leukemia(AML)patients and its relationship with the outcome and prognosis of AML patients.Methods A total of 83 newly diagnosed non-M3 AML patients admitted to the Huai'an First People's Hospital from January 2013 to June 2018 were selected as the research subjects,and they were divided into the CD117 antigenic negative group(CD117-group,n=40)and CD117 antigenic positive group(CD117+group,n=43)according to the immunophenotype flow cytometry detection of bone marrow original cells.The chromosome karyotype of AML patients was analyzed using the R-banding technique,and the gene mutation of AML patients was detected by multiplex reverse transcriptase polymerase chain reaction.Based on the results of chromosome karyotype and gene mutation,the prognosis of all patients was stratified into the good prognosis,the medium prognosis,and the poor prognosis.All patients were treated with one of the following induction regimens according to their condition:(1)IA regimen[idarubicin 10-12 mg·m-2(day 1-3)+cytarabine 100 mg·m-2(day 1-7)];(2)DA regimen[daunorubicin 60-90 mg·m-2(day 1-3)+cytarabine 100 mg·m-2(day 1-7)];(3)HA regimen[homoharringtonine 2.5 mg·m-2(day 1-7)+cytarabine 100 mg·m-2(day 1-7)].Patients who did not reach complete remission(CR)after the first course of induction could choose the original regimen or a new regimen.All patients with CR were treated with high-dose cytarabine(1-2 g·m-2,once in 12 hours,day 1-4)for consolidation chemotherapy.All patients completed one course or more of standard induction chemotherapy.The CR rate,minimal residual disease(MRD)negative rate and the overall survival(OS)of all patients were observed.Results There was no significant difference in chromosome karyotype,FMS-like tyrosine kinase 3(FLT3),CCAAT/enhancer binding protein α(CEBPA),nucleophosmin 1(NPM1)and C-kit gene mutations,and stratified prognosis between the two groups(P＞0.05).The CR rates after the first treatment course in the CD117-and CD117+groups were 77.50％(31/40)and 76.74％(33/43),respectively,showing no statistically significant difference between the two groups(x2=0.007,P＞0.05).The MRD negative rate of CR patients in the CD117-group was 90.30％(28/31),and the MRD negative rate in the CD117+group was 57.60％(19/33).The MRD negative rate of CR patients in the CD117-group was significantly higher than that in the CD117+group(x2=8.797,P＜0.01).The median OS was 33.09[95％confidence interval(CI):28.22-37.97]months in the CD117-group and 20.61(95％CI:17.89-23.33)months in the CD117+group.The median OS in the CD117-group was significantly longer than that in the CD117+group(P＜0.01).Conclusion CD117 is associated with the MRD in non-M3 AML patients and affects the prognosis of AML patients.It is of great significance to guide the clinical treatment of AML patients.
NETL
NSTL
万方数据
